- Home
- ATNI vs TNGX Comparison
ATNI vs TNGX Comparison
Compare ATNI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- TNGX
- Stock Information
- Founded
- ATNI 1987
- TNGX 2014
- Country
- ATNI United States
- TNGX United States
- Employees
- ATNI N/A
- TNGX N/A
- Industry
- ATNI Telecommunications Equipment
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ATNI Telecommunications
- TNGX Health Care
- Exchange
- ATNI Nasdaq
- TNGX Nasdaq
- Market Cap
- ATNI 335.2M
- TNGX 317.4M
- IPO Year
- ATNI 1991
- TNGX N/A
- Fundamental
- Price
- ATNI $22.10
- TNGX $1.75
- Analyst Decision
- ATNI Strong Buy
- TNGX Strong Buy
- Analyst Count
- ATNI 2
- TNGX 7
- Target Price
- ATNI $31.00
- TNGX $12.33
- AVG Volume (30 Days)
- ATNI 82.0K
- TNGX 801.9K
- Earning Date
- ATNI 03-04-2025
- TNGX 05-07-2025
- Dividend Yield
- ATNI 4.39%
- TNGX N/A
- EPS Growth
- ATNI N/A
- TNGX N/A
- EPS
- ATNI N/A
- TNGX N/A
- Revenue
- ATNI $729,075,000.00
- TNGX $42,069,000.00
- Revenue This Year
- ATNI $3.02
- TNGX N/A
- Revenue Next Year
- ATNI $0.27
- TNGX N/A
- P/E Ratio
- ATNI N/A
- TNGX N/A
- Revenue Growth
- ATNI N/A
- TNGX 15.17
- 52 Week Low
- ATNI $14.74
- TNGX $1.71
- 52 Week High
- ATNI $33.72
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- ATNI 70.41
- TNGX 31.59
- Support Level
- ATNI $19.94
- TNGX $1.80
- Resistance Level
- ATNI $23.60
- TNGX $2.04
- Average True Range (ATR)
- ATNI 1.23
- TNGX 0.21
- MACD
- ATNI 0.37
- TNGX 0.01
- Stochastic Oscillator
- ATNI 83.40
- TNGX 3.94
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise US Telecom and International Telecom. The company earns revenue from its telecommunication services.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.